Free Trial

Ayala Pharmaceuticals (ADXS) Competitors

Ayala Pharmaceuticals logo
$0.03 0.00 (0.00%)
As of 05/27/2025

ADXS vs. BFRI, INDP, NLSP, SNGX, MTVA, ENSC, APLM, GTBP, FRTX, and ADIL

Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Biofrontera (BFRI), Indaptus Therapeutics (INDP), NLS Pharmaceutics (NLSP), Soligenix (SNGX), MetaVia (MTVA), Ensysce Biosciences (ENSC), Apollomics (APLM), GT Biopharma (GTBP), Fresh Tracks Therapeutics (FRTX), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.

Ayala Pharmaceuticals vs.

Ayala Pharmaceuticals (NASDAQ:ADXS) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, community ranking, risk and media sentiment.

Ayala Pharmaceuticals has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

In the previous week, Biofrontera had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 5 mentions for Biofrontera and 1 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat Biofrontera's score of -0.50 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ayala Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biofrontera has higher revenue and earnings than Ayala Pharmaceuticals. Biofrontera is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.24M0.46-$48.07M-$7.980.00
Biofrontera$38.00M0.15-$20.13M-$2.26-0.26

Ayala Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -36.31%. Ayala Pharmaceuticals' return on equity of 0.00% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Ayala PharmaceuticalsN/A N/A N/A
Biofrontera -36.31%-565.73%-96.64%

Biofrontera has a consensus price target of $2.75, indicating a potential upside of 359.87%. Given Biofrontera's stronger consensus rating and higher probable upside, analysts plainly believe Biofrontera is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ayala Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Biofrontera
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biofrontera received 9 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 69.23% of users gave Biofrontera an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Ayala PharmaceuticalsOutperform Votes
No Votes
Underperform Votes
87
100.00%
BiofronteraOutperform Votes
9
69.23%
Underperform Votes
4
30.77%

Summary

Biofrontera beats Ayala Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXS vs. The Competition

MetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.49M$6.47B$5.37B$8.49B
Dividend YieldN/A2.65%5.28%4.18%
P/E Ratio0.008.7526.9219.84
Price / Sales0.46255.54398.39139.60
Price / CashN/A65.8538.2534.64
Price / Book-0.026.416.774.54
Net Income-$48.07M$142.98M$3.22B$247.97M
7 Day PerformanceN/A3.51%1.76%1.78%
1 Month PerformanceN/A2.48%7.55%8.82%
1 Year PerformanceN/A0.16%20.38%9.56%

Ayala Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADXS
Ayala Pharmaceuticals
N/A$0.03
flat
N/A-86.0%$1.49M$3.24M0.0020
BFRI
Biofrontera
2.5893 of 5 stars
$0.67
+3.1%
$2.75
+310.5%
-39.1%$6.33M$37.32M-0.3070Gap Up
INDP
Indaptus Therapeutics
3.7685 of 5 stars
$0.39
-13.1%
$8.50
+2,079.5%
-86.1%$6.25MN/A-0.236Positive News
Gap Down
NLSP
NLS Pharmaceutics
N/A$1.71
+5.8%
N/A+1,095.4%$6.15MN/A0.006Gap Down
SNGX
Soligenix
1.2011 of 5 stars
$1.88
+1.1%
N/A-67.3%$6.14M$-117,029.00-0.2520Gap Up
MTVA
MetaVia
1.9354 of 5 stars
$0.70
+2.1%
$7.50
+973.0%
N/A$6.05MN/A0.008Gap Down
ENSC
Ensysce Biosciences
0.1946 of 5 stars
$2.55
+9.0%
N/A-72.2%$6.05M$2.23M-0.0910Gap Down
APLM
Apollomics
0.7771 of 5 stars
$5.40
+10.4%
N/A-74.1%$5.96M$1.22M0.0045
GTBP
GT Biopharma
3.5125 of 5 stars
$2.24
+0.4%
$11.00
+391.1%
-21.5%$5.68MN/A-0.398Gap Up
FRTX
Fresh Tracks Therapeutics
N/A$0.94
-0.5%
N/A+3.9%$5.59M$10.06M-0.6620
ADIL
Adial Pharmaceuticals
3.186 of 5 stars
$0.70
+6.4%
$8.00
+1,042.9%
-46.4%$5.53MN/A-0.4820

Related Companies and Tools


This page (NASDAQ:ADXS) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners